top of page

Our Team

IMMvention is powered by its experienced team with deep expertise in drug discovery and development across multiple therapeutic areas

Don Haut
Don Haut, PhD
Executive Chair
McKinsey & Company
MDCO Company
Aspect
AskBio
Anil Goyal
Anil Goyal, PhD
CEO and Co-founder
Ribo
Millennium Takeda
Serenex
matthew gallovic
Matt Gallovic, PhD
Director of Research
Baxter
UNC Chapel Hill
Sarah Wise
Sarah Wise
Senior Scientist
Gilead
Combinator logo

Consultants

Bridget Martell

Bridget Martell, MD
Artizan Bio / Kura Oncology

Chief Medical Officer

  • Grey LinkedIn Icon
Ryan Clark

Ryan Clark, PhD
Inception, Amira

Head of Chemistry

  • Grey LinkedIn Icon
John Reardon, PhD

John Reardon, PhD
Ribometrix, GSK

Head of R&D

  • Grey LinkedIn Icon
John Dillberger, PhD

John Dillberger, PhD
Triangle Pharmaceuticals, GSK

Head of Toxicology

  • Grey LinkedIn Icon
Steve Smith

Steve Smith
UCB, Roche, Syntex

Head of DMPK

  • Grey LinkedIn Icon
Ben Pratt, PhD

Ben Pratt, PhD
Vasa Therapeutics, Allergan

Head of CMC

  • Grey LinkedIn Icon
IMMvention-Background.png

Board of Directors

EXECUTIVE CHAIR
Don Haut, PhD, Independent
CEO and Director
Anil Goyal, PhD, IMMvention
DIRECTOR and CO-FOUNDER
Jenny Ting, PhD, UNC, Chapel Hill
DIRECTOR
Matt Cohen, PhD, Osage University Partners
DIRECTOR
Ben Scruggs, PhD, Hatteras Venture Partners
DIRECTOR
Natalia Novac, PhD, Delin Ventures
OBSERVER
Caroline Haegeman, PhD, Delin Ventures
OBSERVER
Harry Won, PhD, Osage University Partners
orangeGlow.jpg

Let's collaborate

Interested in partnering with us? Reach out to start the conversation
Immvention mark

© 2024 IMMvention Therapeutix

bottom of page